ARA-290 2mg

ARA-290 is a synthetic 11-amino acid peptide engineered from the helix-B surface domain of erythropoietin (EPO). It is studied in laboratory research for its interaction with the innate repair receptor (IRR), a heteromeric complex composed of the erythropoietin receptor (EPOR) and the beta-common receptor (CD131), which is distinct from the classical EPOR homodimer responsible for red blood cell production.^1,2 This product is studied in vitro and in animal (in vivo) laboratory models and is not intended for human or animal consumption or therapeutic use.

Receptor Binding and Mechanism Research

Laboratory research has characterized ARA-290’s selective activation of the IRR without engaging the classical erythropoietin receptor homodimer, distinguishing its receptor-binding profile from native erythropoietin.^1,2 These structure-function studies contribute to basic research on EPO-derived peptide signaling and receptor pharmacology.

Animal Model Nerve Signaling Research

Animal model studies in rats and beta-common receptor knockout mice have examined ARA-290’s effects on nerve-related signaling and spinal cord inflammatory marker levels following experimentally induced nerve injury.³ These are laboratory observations in animal models and do not establish safety or efficacy for any human or animal application.

Cardiac Tissue Injury Model Research

Animal model research has examined a related non-erythropoietic helix-B peptide’s effects on cell survival markers in models of induced myocardial tissue injury.⁴

In Vitro Cellular Research

In vitro studies using cultured urothelial cells have examined ARA-290’s effects on innate immune signaling markers and cellular response to bacterial exposure.⁵

Important Notice

ARA-290 is intended strictly for in vitro and in vivo (animal) laboratory research only. This product is not intended for human or animal use, has not been evaluated for safety or efficacy in humans or animals, and is not approved by the FDA or any regulatory agency for any use. These findings do not establish safety, efficacy, or suitability for any application outside of controlled laboratory research.

References

1. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008;105(31):10925–10930.
2. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101(41):14907–14912.
3. Swartjes M, et al. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology. 2011;115(5):1084–1092.
4. Ahmet I, Tae HJ, Juhaszova M, et al. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med. 2011;17(3-4):194–200.
5. Polgárová K, Lüthje P, Cerami A, Brauner A. The erythropoietin analogue ARA 290 modulates the innate response and reduces Escherichia coli invasion into urothelial cells. FEMS Immunol Med Microbiol. 2011;62(2):190–196